4ky1: Difference between revisions
No edit summary |
No edit summary |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
== | ==humanized HP1/2 Fab== | ||
[[4ky1]] is a 2 chain structure with sequence from [ | <StructureSection load='4ky1' size='340' side='right'caption='[[4ky1]], [[Resolution|resolution]] 2.97Å' scene=''> | ||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[4ky1]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4KY1 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4KY1 FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.97Å</td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4ky1 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ky1 OCA], [https://pdbe.org/4ky1 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4ky1 RCSB], [https://www.ebi.ac.uk/pdbsum/4ky1 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4ky1 ProSAT]</span></td></tr> | |||
</table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Antibodies are key components of the adaptive immune system and are well-established protein therapeutic agents. Typically high-affinity antibodies are obtained by immunization of rodent species that need to be humanized to reduce their immunogenicity. The complementarity-determining regions (CDRs) contain the residues in a defined loop structure that confer antigen binding, which must be retained in the humanized antibody. To design a humanized antibody, we graft the mature murine CDRs onto a germline human acceptor framework. Structural defects due to mismatches at the graft interface can be fixed by mutating some framework residues to murine, or by mutating some residues on the CDRs' backside to human or to a de novo designed sequence. The first approach, framework redesign, can yield an antibody with binding better than the CDR graft and one equivalent to the mature murine, and reduced immunogenicity. The second approach, CDR redesign, is presented here as a new approach, yielding an antibody with binding better than the CDR graft, and immunogenicity potentially less than that from framework redesign. Application of both approaches to the humanization of anti-alpha4 integrin antibody HP1/2 is presented and the concept of the hybrid humanization approach that retains "difficult to match" murine framework amino acids and uses de novo CDR design to minimize murine amino acid content and reduce cell-mediated cytotoxicity liabilities is discussed. | |||
Antibody humanization by redesign of complementarity-determining region residues proximate to the acceptor framework.,Hanf KJ, Arndt JW, Chen LL, Jarpe M, Boriack-Sjodin PA, Li Y, van Vlijmen HW, Pepinsky RB, Simon KJ, Lugovskoy A Methods. 2013 Jun 28. pii: S1046-2023(13)00225-9. doi:, 10.1016/j.ymeth.2013.06.024. PMID:23816785<ref>PMID:23816785</ref> | |||
<ref | |||
[[Category: | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
[[Category: Arndt | </div> | ||
[[Category: Boriack-Sjodin | <div class="pdbe-citations 4ky1" style="background-color:#fffaf0;"></div> | ||
[[Category: Chen | == References == | ||
[[Category: Hanf | <references/> | ||
[[Category: Jarpe | __TOC__ | ||
[[Category: Li | </StructureSection> | ||
[[Category: Lugovskoy | [[Category: Homo sapiens]] | ||
[[Category: Pepinsky | [[Category: Large Structures]] | ||
[[Category: Silvian | [[Category: Arndt JW]] | ||
[[Category: Taveras | [[Category: Boriack-Sjodin A]] | ||
[[Category: Taylor | [[Category: Chen LL]] | ||
[[Category: Vlijmen | [[Category: Hanf KJM]] | ||
[[Category: Jarpe M]] | |||
[[Category: Li Y]] | |||
[[Category: Lugovskoy A]] | |||
[[Category: Pepinsky B]] | |||
[[Category: Silvian L]] | |||
[[Category: Taveras A]] | |||
[[Category: Taylor F]] | |||
[[Category: Van Vlijmen H]] | |||
Latest revision as of 19:06, 20 September 2023
humanized HP1/2 Fabhumanized HP1/2 Fab
Structural highlights
Publication Abstract from PubMedAntibodies are key components of the adaptive immune system and are well-established protein therapeutic agents. Typically high-affinity antibodies are obtained by immunization of rodent species that need to be humanized to reduce their immunogenicity. The complementarity-determining regions (CDRs) contain the residues in a defined loop structure that confer antigen binding, which must be retained in the humanized antibody. To design a humanized antibody, we graft the mature murine CDRs onto a germline human acceptor framework. Structural defects due to mismatches at the graft interface can be fixed by mutating some framework residues to murine, or by mutating some residues on the CDRs' backside to human or to a de novo designed sequence. The first approach, framework redesign, can yield an antibody with binding better than the CDR graft and one equivalent to the mature murine, and reduced immunogenicity. The second approach, CDR redesign, is presented here as a new approach, yielding an antibody with binding better than the CDR graft, and immunogenicity potentially less than that from framework redesign. Application of both approaches to the humanization of anti-alpha4 integrin antibody HP1/2 is presented and the concept of the hybrid humanization approach that retains "difficult to match" murine framework amino acids and uses de novo CDR design to minimize murine amino acid content and reduce cell-mediated cytotoxicity liabilities is discussed. Antibody humanization by redesign of complementarity-determining region residues proximate to the acceptor framework.,Hanf KJ, Arndt JW, Chen LL, Jarpe M, Boriack-Sjodin PA, Li Y, van Vlijmen HW, Pepinsky RB, Simon KJ, Lugovskoy A Methods. 2013 Jun 28. pii: S1046-2023(13)00225-9. doi:, 10.1016/j.ymeth.2013.06.024. PMID:23816785[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||